Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Human immunodeficiency virus 1 | Human immunodeficiency virus type 1 integrase | Starlite/ChEMBL | References |
Species | Potential target | Known druggable target/s | Ortholog Group |
---|---|---|---|
Trypanosoma brucei | RNA helicase, putative | Get druggable targets OG5_139608 | All targets in OG5_139608 |
Plasmodium yoelii | integrase-related | Get druggable targets OG5_139608 | All targets in OG5_139608 |
Schistosoma mansoni | hypothetical protein | Get druggable targets OG5_139608 | All targets in OG5_139608 |
Trypanosoma congolense | RNA helicase, putative | Get druggable targets OG5_139608 | All targets in OG5_139608 |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus granulosus | serotonin transporter | 0.194 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.194 | 1 | 1 |
Loa Loa (eye worm) | solute carrier family 6 member 4 | 0.194 | 1 | 1 |
Plasmodium vivax | amine transporter, putative | 0.0329 | 0 | 0.5 |
Chlamydia trachomatis | Ssodium-dependent amino acid transporter | 0.0329 | 0 | 0.5 |
Schistosoma mansoni | sodium/chloride dependent transporter | 0.194 | 1 | 1 |
Toxoplasma gondii | hypothetical protein | 0.0329 | 0 | 0.5 |
Treponema pallidum | sodium- and chloride- dependent transporter | 0.194 | 1 | 0.5 |
Toxoplasma gondii | Sodium:neurotransmitter symporter family protein | 0.0329 | 0 | 0.5 |
Toxoplasma gondii | Sodium:neurotransmitter symporter family protein | 0.0329 | 0 | 0.5 |
Loa Loa (eye worm) | norepinephrine transporter | 0.194 | 1 | 1 |
Toxoplasma gondii | hypothetical protein | 0.0329 | 0 | 0.5 |
Loa Loa (eye worm) | serotonin transporter b | 0.194 | 1 | 1 |
Toxoplasma gondii | Sodium:neurotransmitter symporter family protein | 0.0329 | 0 | 0.5 |
Echinococcus multilocularis | serotonin transporter | 0.194 | 1 | 1 |
Plasmodium vivax | hypothetical protein, conserved | 0.0329 | 0 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.194 | 1 | 1 |
Onchocerca volvulus | 0.194 | 1 | 1 | |
Loa Loa (eye worm) | hypothetical protein | 0.194 | 1 | 1 |
Plasmodium falciparum | amino acid transporter, putative | 0.0329 | 0 | 0.5 |
Plasmodium falciparum | transporter, putative | 0.0329 | 0 | 0.5 |
Schistosoma mansoni | norepinephrine/norepinephrine transporter | 0.194 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
ED50 (functional) | = 7.8 uM | Effective dose of the compound against L-chicoric acid-resistant molecular clone of HIV-1NL4-3 | ChEMBL. | 9986720 |
ED50 (functional) | = 8.4 uM | Concentration that inhibits Human Immunodeficiency Virus Type 1 (HIV-1)-induced death of MT-2 cells | ChEMBL. | 9986720 |
ED50 (functional) | = 31.25 uM | Effective dose of the compound against L-chicoric acid-resistant molecular clone of HIV-1NL4-3 clone1-D4 | ChEMBL. | 9986720 |
IC50 (binding) | = 2.38 uM | Inhibitory activity against Human Immunodeficiency Virus Type 1 integrase (HIV-1 IN) in the disintegration assay. | ChEMBL. | 9986720 |
IC50 (binding) | = 2.38 uM | Inhibitory activity against Human Immunodeficiency Virus Type 1 integrase (HIV-1 IN) in the disintegration assay. | ChEMBL. | 9986720 |
Inhibition (binding) | = 94.5 % | Inhibition of Human Immunodeficiency Virus Type 1 integrase (HIV-1 IN) in the disintegration reaction at a concentration of 25 microM. | ChEMBL. | 9986720 |
Inhibition (binding) | = 94.5 % | Inhibition of Human Immunodeficiency Virus Type 1 integrase (HIV-1 IN) in the disintegration reaction at a concentration of 25 microM. | ChEMBL. | 9986720 |
LD5 (ADMET) | > 263 uM | Lethal dose (LD5) concentration inhibiting growth of MT-2 cells by 5% | ChEMBL. | 9986720 |
LD5 (ADMET) | > 263 uM | Lethal dose (LD5) concentration inhibiting growth of MT-2 cells by 5% | ChEMBL. | 9986720 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.